Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

NCT04315233 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Recurrent Ovarian Carcinoma

Interventions

DRUG: Ribociclib
DRUG: Belinostat

Sponsor

University of Utah

Collaborators

[object Object]
[object Object]